Market Overview

UPDATE: Morgan Stanley Initiates Quintiles Transnational at Overweight on CRO Market Leader Position

Share:
Related
Stocks Hitting 52-Week Highs
Jefferies Boosts Targets Across Pharmaceutical Service Stocks
Quintiles prices equity offering from existing shareholders (Seeking Alpha)

In a report published Tuesday, Morgan Stanley analyst Ricky R. Goldwasser initiated coverage on Quintiles Transnational (NYSE: Q) with an Overweight rating and $51.00 price target.

In the report, Morgan Stanley noted, “As the contract research organization (CRO) market leader with 11% share of clinical outsourcing, a diversified customer base and backlog visibility, we believe Quintiles is best positioned to benefit from the growth in biopharmaceutical R&D outsourcing.”

Quintiles Transnational closed on Monday at $43.53.

Latest Ratings for Q

DateFirmActionFromTo
Jul 2015KeyBancUpgradesSectorweightOverweight
Jul 2015SunTrust Robinson HumphreyMaintainsBuy
May 2015JefferiesMaintainsBuy

View More Analyst Ratings for Q
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Initiation Analyst Ratings

 

Related Articles (Q)

Get Benzinga's Newsletters